Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone

Alcoholism: Clinical and Experimental Research

Volumn 30, Issue 3, 2006, Pages 480-490

  Dunbar, Joi L ^a   Turncliff, Ryan Z ^a   Dong, Qunming ^a   Silverman, Bernard L ^a   Ehrich, Elliot W ^a   Lasseter, Kenneth C ^b  

^a ALKERMES INC   (United States)

^b SFBC International   (United States)

Author keywords

Extended Release Preparation; Long acting Injectable; Naltrexone; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; LONG ACTING DRUG; MICROSPHERE; NALTREXOL; NALTREXONE; PLACEBO;

ADULT; ALCOHOLISM; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED DRUG RELEASE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FIRST PASS EFFECT; HUMAN; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALCOHOL DETERRENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INJECTIONS; LACTIC ACID; MALE; MICROSPHERES; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POLYGLYCOLIC ACID; POLYMERS; SEX CHARACTERISTICS;

EID: 33644771227     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2006.00052.x     Document Type: Article

References (45)

1. Anton RF Drobes DJ Voronin K Durazo-Avizu R Moak D 2004 Naltrexone effects on alcohol consumption in a clinical laboratory paradigm temporal effects of drinking Psychopharmacology (Berlin) 173 32 40
2. Bartus RT Emerich DF Hotz J Blaustein M Dean RL Perdomo B Basile AS 2003 Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats Neuropsychopharmacology 28 1973 1982
3. Breyer-Pfaff U Nill K 2004 Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol J Pharm Pharmacol 56 1601 1606
4. Chiang CN Hollister LE Kishimoto A Barnett G 1984 Kinetics of a naltrexone sustained-release preparation Clin Pharmacol Ther 36 704 708
5. Chick J Anton R Checinski K Croop R Drummond DC Farmer R Labriola D Marshall J Moncrieff J Morgan MY Peters T Ritson B 2000 A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse Alcohol 35 587 593
6. Comer SD Collins ED Kleber HD Nuwayser ES Kerrigan JH Fischman MW 2002 Depot naltrexone long-lasting antagonism of the effects of heroin in humans Psychopharmacology 159 351 360
7. Croop RS Faulkner EB Labriola DF 1997 The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The naltrexone usage study group Arch Gen Psychiatry 54 1130 1135
8. Davidson D Palfai T Bird C Swift R 1999 Effects of naltrexone on alcohol self-administration in heavy drinkers Alcohol Clin Exp Res 23 195 203
9. Drobes DJ Anton RF Thomas SE Voronin K 2003 A clinical laboratory paradigm for evaluating medication effects on alcohol consumption naltrexone and nalmefene Neuropsychopharmacology 28 755 764
10. Funck-Brentano C Jaillon P 1993 Rate-corrected QT interval techniques and limitations Am J Cardiol 72 17B 22B
11. Galloway GP Koch M Cello R Smith DE 2005 Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics an open-label trial BMC Psychiatr 5 18
12. Garbutt JC Kranzler HR O'Malley SS Gastfriend DR Pettinati HM Silverman BL Loewy JW Ehrich EW 2005 Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence a randomized controlled trial JAMA 293 1617 1625
13. Gibaldi M Perrier D 1982a Multiple dosing in Pharmacokinetics Swarbrick J ed) pp 113 144 Marcel Dekker New York
14. Gibaldi M Perrier D 1982b Prediction of drug concentrations on multiple dosing using the principle of superposition in Pharmacokinetics pp 451 457 Marcel Dekker New York
15. Heishman SJ Francis-Wood A Keenan RM Chiang CN Terrill JB Tia B Henningfield JE 1993 Safety and pharmacokinetics of a new formulation of depot naltrexone NIDA Res Monogr 141 82
16. Hulse GK Arnold-Reed DE O'Neil G Chan CT Hansson R O'Neil P 2004a Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant comparing two naltrexone implants Addict Biol 9 59 65
17. Hulse GK Arnold-Reed DE O'Neil G Chan CT Hansson RC 2004b Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants Addict Biol 9 67 72
18. King AC Volpicelli JR Gunduz M O'Brien CP Kreek MJ 1997 Naltrexone biotransformation and incidence of subjective side effects a preliminary study Alcohol Clin Exp Res 21 906 909
19. Kogan MJ Verebey K Mule SJ 1977 Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration Res Commun Chem Pathol Pharmacol 18 29 34
20. Kranzler HR Modesto-Lowe V Nuwayser ES 1998 Sustained-release naltrexone for alcoholism treatment a preliminary study Alcohol Clin Exp Res 22 1074 1079
21. Lee MC Wagner HN Jr. Tanada S Frost JJ Bice AN Dannals RF 1988 Duration of occupancy of opiate receptors by naltrexone J Nucl Med 29 1207 1211
22. Leshner AI 2003 Understanding drug addiction insights from the research in Principles of Addiction Medicine Graham AW et al eds), pp 47 45 American Society of Addiction Medicine Chevy Chase, MD
23. Lewis DH 1990 Controlled release of bioactive agents from lactide/glycolide polymers in Biodegradable Polymers as Drug Delivery Systems Chasin M Langer R eds), pp 1 41 Marcel Dekker New York
24. Litten RZ Fertig J Mattson M Egli M 2005 Development of medications for alcohol use disorders: recent advances and ongoing challenges Expert Opin Emerg Drugs 10 323 343
25. Mason BJ Goodman AM Dixon RM Hameed MH Hulot T Wesnes K Hunter JA Boyeson MG 2002 A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone Neuropsychopharmacology 27 596 606
26. McCaul ME Wand GS Rohde C Lee SM 2000 Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers Alcohol Clin Exp Res 24 1385 1391
27. McCaul ME Wand GS Stauffer R Lee SM Rohde CA 2001 Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation Neuropsychopharmacology 25 537 547
28. Meyer MC Straughn AB Lo MW Schary WL Whitney CC 1984 Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration J Clin Psychiatry 45 15 19
29. Mitchell JE Morley JE Levine AS Hatsukami D Gannon M Pfohl D 1987 High-dose naltrexone therapy and dietary counseling for obesity Biol Psychiatry 22 35 42
30. Monti PM Rohsenow DJ Swift RM Gulliver SB Colby SM Mueller TI Brown RA Gordon A Abrams DB Niaura RS Asher MK 2001 Naltrexone and cue exposure with coping and communication skills training for alcoholics treatment process and 1-year outcomes Alcohol Clin Exp Res 25 1634 1647
31. O'Malley SS Jaffe AJ Chang G Schottenfeld RS Meyer RE Rounsaville B 1992 Naltrexone and coping skills therapy for alcohol dependence. A controlled study Arch Gen Psychiatry 49 881 887
32. O'Malley SS Krishnan-Sarin S Farren C Sinha R Kreek MJ 2002 Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis Psychopharmacology (Berlin) 160 19 29
33. Ohara H Miyabe Y Deyashiki Y Matsuura K Hara A 1995 Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver Biochem Pharmacol 50 221 227
34. Oncken C Van Kirk J Kranzler HR 2001 Adverse effects of oral naltrexone analysis of data from two clinical trials Psychopharmacology (Berlin) 154 397 402
35. Perez-Reyes M Wall ME 1981 A comparative study of the oral, intravenous, and subcutaneous administration of 3H-naltrexone to normal male volunteers NIDA Res Monogr 28 93 101
36. Porter SJ Somogyi AA White JM 2000 Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol Br J Clin Pharmacol 50 465 471
37. Porter SJ Somogyi AA White JM 2002 In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone Addict Biol 7 219 225
38. Rinn W Desai N Rosenblatt H Gastfriend DR 2002 Addiction denial and cognitive dysfunction a preliminary investigation J Neuropsychiatry Clin Neurosci 14 52 57
39. Rohsenow DJ Colby SM Monti PM Swift RM Martin RA Mueller TI Gordon A Eaton CA 2000 Predictors of compliance with naltrexone among alcoholics Alcohol Clin Exp Res 24 1542 1549
40. Silber BM Bailer M Yacobi A 1987 Pharmacokinetic/pharmacodynamic basis of controlled drug delivery in Controlled Drug Delivery Fundamentals and Applications Robinson JR Lee VH eds), pp 213 251 Marcel Dekker New York
41. Srisurapanont M Jarusuraisin N 2005 Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev CD001867.
42. Verebey K Volavka J Mule SJ Resnick RB 1976 Naltrexone disposition, metabolism, and effects after acute and chronic dosing Clin Pharmacol Ther 20 315 328
43. Volpicelli JR Alterman AI Hayashida M O'Brien CP 1992 Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry 49 876 880
44. Volpicelli JR Rhines KC Rhines JS Volpicelli LA Alterman AI O'Brien CP 1997 Naltrexone and alcohol dependence. Role of subject compliance Arch Gen Psychiatry 54 737 742
45. Wall ME Brine DR Perez-Reyes M 1981 Metabolism and disposition of naltrexone in man after oral and intravenous administration Drug Metab Dispos 9 369 375